The prominent biotech investment trust has appointed a new director with extensive public health leadership experience, as the company navigates the integration of multiple agencies into a unified health security organization.
The prominent investment trust has released its monthly fact sheet, providing an update on its portfolio and activities.
The retailer has announced a capital reduction to provide more flexibility for future share buybacks or returns of capital.
The prominent investment trust is facing challenges, according to its latest update.
The prominent investment trust has released its monthly fact sheet, providing an update on the company's status.
The prominent investment trust has announced the appointment of a new non-executive director to its board.
The prominent investment trust has released its monthly fact sheet, providing an update on its portfolio and activities.
The prominent investment trust has announced a non-executive director has acquired a small number of shares in the company.
The prominent investment trust has announced that one of its non-executive directors has acquired 10,000 ordinary shares in the company.
The investment trust reported a 24.4% decline in net asset value per share, citing macroeconomic factors and regulatory issues as key challenges during the year.